TELIX Pharmaceuticals Ltd Asset Resilience Ratio

Latest as of June 2018: 32.29%

TELIX Pharmaceuticals Ltd asset resilience ratio. TELIX Pharmaceuticals Ltd (TLX) has an Asset Resilience Ratio of 32.29% as of June 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TELIX Pharmaceuticals Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$15.67 Million

≈ $11.08 Million USD Cash + Short-term Investments

Total Assets

AU$48.51 Million

≈ $34.32 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of TELIX Pharmaceuticals Ltd (None–None)

Asset resilience ratio of TELIX Pharmaceuticals Ltd from None to None. This chart shows how TELIX Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See TELIX Pharmaceuticals Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down TELIX Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of TELIX Pharmaceuticals Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$15.67 Million	32.29%
Total Liquid Assets	AU$15.67 Million	32.29%

Asset Resilience Insights

Very High Liquidity: TELIX Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 32.29% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

TELIX Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare TELIX Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

TELIX Pharmaceuticals Ltd Asset Resilience Ratio by Year (None–None)

TELIX Pharmaceuticals Ltd asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for TELIX Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.11 Billion

AU$4.39 Billion AUD

Market Cap Rank

#4633 Global

#118 in Australia

Share Price

AU$13.13

Change (1 day)

-2.60%

52-Week Range

AU$8.63 - AU$17.85

All Time High

AU$31.14